Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
CARMIEL, Israel, June 30, 2025 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the Company has been added to the Russell 3000® and Russell 2000® Indexes, effective as of the […]
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® Read Post »
Press




